[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521916":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":118,"collaborators":120,"id":124,"slug":36,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":36,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":36,"enrollmentInfo":132,"targetDuration":36,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":44,"whyStopped":36,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"MBQ Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MBQ-167 oral capsule","EXPERIMENTAL","A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design",[13],"Drug: MBQ-167",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","MBQ-167","MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42",[9],[21,22,23,24,25],"Rac and Cdc42 inhibitor","Rac inhibitor","Cdc42 inhibitor","PAK inhibitor","Rac\u002FCdc42 inhibitor",[27],{"name":28,"affiliation":29,"role":30},"Neil Sankar, MD","CMO, MBQ Pharma","STUDY_DIRECTOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Scott Houston","CONTACT","(415) 404 8838",null,"scott.houston@mbqpharma.com",{"name":39,"role":34,"phone":36,"phoneExt":36,"email":40},"Jose Rodriguez-Orengo, PhD","jose.rodriguez@mbqpharma.com",[42,66,82,99],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Precision Next Gen Oncology & Research Center","RECRUITING","Beverly Hills","California","90212","United States",{"type":50,"coordinates":51},"Point",[52,53],-118.40036,34.07362,{"lat":53,"lon":52},[56,60,63],{"name":57,"role":34,"phone":58,"phoneExt":36,"email":59},"Rebecca Godin","424-777-0708","RebeccaG@NextGenOnc.com",{"name":61,"role":34,"phone":58,"phoneExt":36,"email":62},"Francisco Capilla","FranciscoC@NextGenOnc.com",{"name":64,"role":65,"phone":36,"phoneExt":36,"email":36},"Kumar Sankhala, MD","PRINCIPAL_INVESTIGATOR",{"facility":67,"status":44,"city":68,"state":69,"zip":70,"country":48,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Florida Cancer Specialists \u002F Sarah Cannon Research Institute \u002F SCRI","Sarasota","Florida","34232",{"type":50,"coordinates":72},[73,74],-82.53065,27.33643,{"lat":74,"lon":73},[77,81],{"name":78,"role":34,"phone":79,"phoneExt":36,"email":80},"Judy S Wang, MD","941-377-9993","jswang@flcancer.com",{"name":78,"role":65,"phone":36,"phoneExt":36,"email":36},{"facility":83,"status":44,"city":84,"state":85,"zip":86,"country":48,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Sarah Cannon Research Institute\u002FSCRI","Nashville","Tennessee","37203",{"type":50,"coordinates":88},[89,90],-86.78444,36.16589,{"lat":90,"lon":89},[93,97],{"name":94,"role":34,"phone":95,"phoneExt":36,"email":96},"Melissa Sindler","844-482-4812","scri.ddureferrals@scri.com",{"name":98,"role":65,"phone":36,"phoneExt":36,"email":36},"Denise Yardley, MD",{"facility":100,"status":44,"city":101,"state":36,"zip":102,"country":103,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"FDI Clinical Research","San Juan","00927","Puerto Rico",{"type":50,"coordinates":105},[106,107],-66.10572,18.46633,{"lat":107,"lon":106},[110,114,117],{"name":111,"role":34,"phone":112,"phoneExt":36,"email":113},"Mirelis Acosta-Rivera, MD","(787) 722-1248","info@fdipr.com",{"name":115,"role":34,"phone":112,"phoneExt":36,"email":116},"Michelle Echeandia, MT, MSMT","mecheandia@fdipr.com",{"name":111,"role":65,"phone":36,"phoneExt":36,"email":36},{"type":119,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[121],{"name":122,"class":123},"Congressionally Directed Medical Research Programs","FED","100521916",false,"NCT06075810","A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer","A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer","Key Inclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.\n* Histologically and\u002For cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.\n* Participants with known brain metastases may be eligible if specific conditions are met.\n* Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.\n* Are able to swallow capsules twice daily with a meal.\n\nKey Exclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.\n* Females who are pregnant or breastfeeding.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Active malignancies other than advanced breast cancer will be excluded from the study.","ALL","21 Years",{"count":133,"type":134},48,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.",[140,141,142],"Breast Cancer","Breast Neoplasm","Breast Cancer Stage IV",[144,145,146],"Advanced Breast Cancer","Metastatic Breast Cancer","Recurrent Breast Cancer","2024-12-09",{"date":149,"type":150},"2024-12-12","ACTUAL",{"date":152,"type":150},"2023-11-09",{"date":154,"type":134},"2025-10-31",{"name":5,"class":6},4]